Monique M.E.M. Bos

2.8k total citations · 1 hit paper
36 papers, 2.1k citations indexed

About

Monique M.E.M. Bos is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Monique M.E.M. Bos has authored 36 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Monique M.E.M. Bos's work include Cancer Genomics and Diagnostics (10 papers), Cancer Treatment and Pharmacology (8 papers) and Renal cell carcinoma treatment (6 papers). Monique M.E.M. Bos is often cited by papers focused on Cancer Genomics and Diagnostics (10 papers), Cancer Treatment and Pharmacology (8 papers) and Renal cell carcinoma treatment (6 papers). Monique M.E.M. Bos collaborates with scholars based in Netherlands, Germany and Austria. Monique M.E.M. Bos's co-authors include Martin H. Prins, Geertjan van Tienhoven, Dick J. Richel, Franco Piovella, Anthonie W.A. Lensing, Clara Klerk, Harry R. Büller, Hans-Martin Otten, Susanne M. Smorenburg and Paolo Prandoni and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Monique M.E.M. Bos

36 papers receiving 2.1k citations

Hit Papers

Phase I Studies of Anti–Epidermal Growth Factor Receptor ... 2000 2026 2008 2017 2000 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
    2000 596 citations José Baselga, David G. Pfister et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monique M.E.M. Bos Netherlands 19 1.1k 667 527 407 322 36 2.1k
Norbert Marschner Germany 25 1.3k 1.2× 649 1.0× 407 0.8× 349 0.9× 135 0.4× 153 2.2k
Xiaolei Zhu China 14 830 0.8× 678 1.0× 604 1.1× 201 0.5× 235 0.7× 35 2.1k
Carlo Tondini Italy 28 1.2k 1.1× 476 0.7× 363 0.7× 567 1.4× 86 0.3× 104 2.3k
Piotr Czaykowski Canada 23 857 0.8× 1.2k 1.8× 796 1.5× 604 1.5× 130 0.4× 89 2.2k
Mohammad Jahanzeb United States 21 855 0.8× 486 0.7× 190 0.4× 229 0.6× 627 1.9× 69 1.7k
Fabio A.B. Schutz United States 21 1.4k 1.3× 1.2k 1.7× 638 1.2× 281 0.7× 132 0.4× 46 2.9k
H. Anderson Sweden 28 1.4k 1.3× 603 0.9× 254 0.5× 582 1.4× 192 0.6× 51 2.8k
Gianmauro Numico Italy 28 1.1k 1.1× 776 1.2× 569 1.1× 399 1.0× 110 0.3× 115 2.6k
Jamey Skillings Canada 18 1.3k 1.2× 514 0.8× 281 0.5× 260 0.6× 126 0.4× 40 2.1k
Rodolfo Passalacqua Italy 28 2.1k 1.9× 1.3k 1.9× 438 0.8× 543 1.3× 411 1.3× 140 3.7k

Countries citing papers authored by Monique M.E.M. Bos

Since Specialization
Citations

This map shows the geographic impact of Monique M.E.M. Bos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monique M.E.M. Bos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monique M.E.M. Bos more than expected).

Fields of papers citing papers by Monique M.E.M. Bos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monique M.E.M. Bos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monique M.E.M. Bos. The network helps show where Monique M.E.M. Bos may publish in the future.

Co-authorship network of co-authors of Monique M.E.M. Bos

This figure shows the co-authorship network connecting the top 25 collaborators of Monique M.E.M. Bos. A scholar is included among the top collaborators of Monique M.E.M. Bos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monique M.E.M. Bos. Monique M.E.M. Bos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bos, Monique M.E.M., Jelmer E. Oor, Lucas Goense, et al.. (2024). Association Between Physical Activity and Pancreatic Cancer Risk and Mortality: A Systematic Review and Meta-Analysis. Cancers. 16(21). 3594–3594. 2 indexed citations
2.
Tamminga, Sietske J., Jos Verbeek, Monique M.E.M. Bos, et al.. (2019). Two-Year Follow-Up of a Multi-centre Randomized Controlled Trial to Study Effectiveness of a Hospital-Based Work Support Intervention for Cancer Patients. Journal of Occupational Rehabilitation. 29(4). 701–710. 15 indexed citations
3.
Kok, Marleen, Erik van Werkhoven, Mark Opdam, et al.. (2018). Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). European Journal of Cancer. 102. 40–48. 10 indexed citations
4.
Rier, Hánah N., Mark‐David Levin, Joost van Rosmalen, et al.. (2017). First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy. The Oncologist. 22(8). 901–909. 16 indexed citations
5.
Lam, Siu W., Nienke M. Nota, Agnes Jager, et al.. (2016). Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy. Clinical Cancer Research. 22(7). 1611–1620. 17 indexed citations
6.
Schneider, T, Djoeke de Wit, Thera P. Links, et al.. (2016). Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. The Journal of Clinical Endocrinology & Metabolism. 102(2). jc.2016–2525. 76 indexed citations
7.
Baas, Jara M., Monique M.E.M. Bos, Johanneke E.A. Portielje, et al.. (2015). Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. Anti-Cancer Drugs. 26(8). 872–877. 17 indexed citations
8.
Eichelberg, Christian, Walter L. Vervenne, Maria De Santis, et al.. (2015). SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology. 68(5). 837–847. 111 indexed citations
9.
Soest, Robert J. van, Annemieke J.M. Nieuweboer, Ellen S. de Morrée, et al.. (2015). The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. European Journal of Cancer. 51(17). 2562–2569. 47 indexed citations
10.
Onstenk, Wendy, Jaco Kraan, Bianca Mostert, et al.. (2014). Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Molecular Cancer Therapeutics. 14(3). 821–827. 47 indexed citations
11.
Wissing, Michel D., Jules L.L.M. Coenen, Pieter van den Berg, et al.. (2014). CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel. International Journal of Cancer. 136(6). E760–72. 38 indexed citations
12.
13.
Michel, Maurice Stephan, Walter L. Vervenne, Maria De Santis, et al.. (2014). SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 32(4_suppl). 393–393. 32 indexed citations
14.
Bos, Monique M.E.M., Ferishta Bakhshi‐Raiez, Jan Willem T. Dekker, Nicolette F. de Keizer, & Evert de Jonge. (2013). Outcomes of Intensive Care Unit admissions after elective cancer surgery. European Journal of Surgical Oncology. 39(6). 584–592. 20 indexed citations
15.
Tamminga, Sietske J., Jos Verbeek, Monique M.E.M. Bos, et al.. (2013). Effectiveness of a Hospital-Based Work Support Intervention for Female Cancer Patients – A Multi-Centre Randomised Controlled Trial. PLoS ONE. 8(5). e63271–e63271. 67 indexed citations
16.
17.
Bueno-de-Mesquita, Jolien M., Sabine C. Linn, Richard Keijzer, et al.. (2008). Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Research and Treatment. 117(3). 483–495. 131 indexed citations
18.
Tol, J., Annemieke Cats, Linda Mol, et al.. (2008). Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investigational New Drugs. 26(4). 393–397. 53 indexed citations
19.
Klerk, Clara, Susanne M. Smorenburg, Hans-Martin Otten, et al.. (2005). The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy. Journal of Clinical Oncology. 23(10). 2130–2135. 481 indexed citations
20.
Baselga, José, David G. Pfister, Michael R. Cooper, et al.. (2000). Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin. Journal of Clinical Oncology. 18(4). 904–904. 596 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norbert Marschner Breakdown of academic impact, for papers by Xiaolei Zhu Breakdown of academic impact, for papers by Carlo Tondini Breakdown of academic impact, for papers by Piotr Czaykowski Breakdown of academic impact, for papers by Mohammad Jahanzeb Breakdown of academic impact, for papers by Fabio A.B. Schutz Breakdown of academic impact, for papers by H. Anderson Breakdown of academic impact, for papers by Gianmauro Numico Breakdown of academic impact, for papers by Jamey Skillings Breakdown of academic impact, for papers by Rodolfo Passalacqua
Rankless by CCL
2026